Drug Type Small molecule drug |
Synonyms Carisbamate (USAN), Comfyde + [3] |
Mechanism Neurotransmitter receptor modulators |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC9H10ClNO3 |
InChIKeyOLBWFRRUHYQABZ-MRVPVSSYSA-N |
CAS Registry194085-75-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D06573 | Carisbamate |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Seizures | Phase 3 | ES | 28 Apr 2022 | |
Seizures | Phase 3 | PT | 28 Apr 2022 | |
Seizures | Phase 3 | PL | 28 Apr 2022 | |
Seizures | Phase 3 | AR | 28 Apr 2022 | |
Epilepsy | Phase 3 | EU | - | |
Epilepsy | Phase 3 | US | - | |
Lennox Gastaut Syndrome | Phase 3 | - | - | |
Epilepsy, Partial, Motor | Phase 1 | - | 01 Jan 2009 | |
Status Epilepticus | Phase 1 | - | 01 Jan 2009 | |
Epilepsy, Complex Partial | Phase 1 | - | 01 Nov 2006 |
Phase 1/2 | 11 | Placebo (Placebo) | jtegcvetpb(txzlseupcv) = mfzipknegz nmfrjwzbil (vcqvjupjmx, qkmgqhvopa - hzlmpzfphs) View more | - | 02 Mar 2021 | ||
(Carisbamate) | jtegcvetpb(txzlseupcv) = eyjfegwtzg nmfrjwzbil (vcqvjupjmx, wcsmmoiqql - ikyaroyntt) View more | ||||||
Phase 3 | 547 | syelvqpiqr(orfskfxzjt) = Dizziness was the most common treatment-emergent adverse event, with a higher incidence (≥ 5% difference) in the combined carisbamate group (31%) than placebo (9%); the incidence was higher with carisbamate 1,200 mg (32%, n = 58) than with carisbamate 800 mg (30%, n = 53) wreuderpad (mumhhfizdc ) | Negative | 01 Apr 2011 | |||
Not Applicable | - | wngevvfuqq(nzjnlikvgt) = low behavioral/psychiatric adverse event rates dueykydpsu (abaeufyeij ) View more | Positive | 02 Jul 2009 | |||
Not Applicable | 419 | fhpglwssdv(gshsehsdyu) = low behavioral/psychiatric adverse event rates scuunlsmjn (msbqbgubsw ) View more | Positive | 02 Jul 2009 |